Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05880355 · ClinicalTrials.gov registry record · Early Phase 1
Multimodality Cardiovascular Imaging for the Translation of Therapies for Vascular Activation After MI
A Early Phase 1 study, sponsored by University of Virginia.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 60
- Enrollment target
NCT05880355 is a Early Phase 1 study that has not yet begun recruiting, run by University of Virginia. The registered enrollment target is 60 participants.
The verdict
NCT05880355, a Early Phase 1 study, has not yet begun recruiting, sponsored by University of Virginia.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
Subjects with urgently reperfused type I myocardial infarction (MI) will be recruited and randomized to receive either placebo or the oral inflammasome (NLRP3) inhibitor dapansutrile. The primarily outcome measure will be carotid plaque volume change over 6 months; secondary outcome measures will be plaque inflammatory activity and coronary microvascular function.
Interventions
- OTHER Placebo
- DRUG Dapansutrile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2029-01-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05880355
The ClinicalTrials.gov registry entry for NCT05880355 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05880355 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05880355 about?
NCT05880355 is a clinical study titled "Multimodality Cardiovascular Imaging for the Translation of Therapies for Vascular Activation After MI". Subjects with urgently reperfused type I myocardial infarction (MI) will be recruited and randomized to receive either placebo or the oral inflammasome (NLRP3) inhibitor dapansutrile. The primarily outcome measure will be carotid plaque volume change over 6 months; secondary outcome measures will be...
What is the current status of trial NCT05880355?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 60 participants. The study started on 2026-04-01. Estimated completion is 2029-01-30.
What interventions are being tested in trial NCT05880355?
The interventions under investigation include: Placebo (OTHER), Dapansutrile (DRUG).
Who is sponsoring clinical trial NCT05880355?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.